The effects of patient type on physical and mental health of caregivers in France, Germany, Italy, Spain and the United Kingdom

被引：0
|
作者：
Kannan, H. [1 ]
Bolge, S. C. [1 ]
机构：
[1] Consumer Hlth Sci, Princeton, NJ USA
来源：
VALUE IN HEALTH | 2007年 / 10卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)68798-0
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A85 / A86
页数：2
相关论文
共 50 条
  • [41] DISABILITY ADJUSTED LIFE YEARS LOST DUE TO DIABETES IN FRANCE, ITALY, GERMANY, SPAIN AND THE UNITED KINGDOM: A BURDEN OF ILLNESS STUDY
    Darba, J.
    Kaskens, L.
    Detournay, B.
    Ramirez de Arellano, A.
    VALUE IN HEALTH, 2014, 17 (03) : A262 - A262
  • [42] The annual cost of dry eye syndrome in France, Germany, Italy, Spain, Sweden and the United Kingdom among patients managed by ophthalmologists
    Clegg, John P.
    Guest, Julian F.
    Lehman, Almut
    Smith, Andrew F.
    OPHTHALMIC EPIDEMIOLOGY, 2006, 13 (04) : 263 - 274
  • [43] Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom
    Svedbom, A.
    Hadji, P.
    Hernlund, E.
    Thoren, R.
    McCloskey, E.
    Stad, R.
    Stollenwerk, B.
    OSTEOPOROSIS INTERNATIONAL, 2019, 30 (09) : 1745 - 1754
  • [44] Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom
    A. Svedbom
    P. Hadji
    E. Hernlund
    R. Thoren
    E. McCloskey
    R. Stad
    B. Stollenwerk
    Osteoporosis International, 2019, 30 : 1745 - 1754
  • [45] EXPLAINING THE DISPARITIES OF MARKET ACCESS FOR GLIFLOZINS IN FRANCE, SPAIN, GERMANY AND THE UNITED-KINGDOM
    Bodaghi, C.
    Benque, E.
    Troubat, A.
    VALUE IN HEALTH, 2018, 21 : S134 - S134
  • [46] Future long-term care expenditure in Germany, Spain, Italy and the United Kingdom
    Comas-Herrera, A
    Wittenberg, R
    Costa-Font, J
    Gori, C
    Di Maio, A
    Patxot, C
    Pickard, L
    Pozzi, A
    Rothgang, H
    AGEING & SOCIETY, 2006, 26 : 285 - 302
  • [47] Comparison of Lost Productivity Due to Eculizumab and Ravulizumab Treatments for Paroxysmal Nocturnal Hemoglobinuria in France, Germany, Italy, Russia, Spain, the United Kingdom, and the United States
    Levy, Adrian R.
    Dysart, Laura
    Patel, Yogesh
    Briggs, Andrew
    Schneider, John
    Myren, Karl-Johan
    Tomazos, Ioannis
    BLOOD, 2019, 134
  • [48] Preparing for the upcoming 2022/23 influenza season: A modelling study of the susceptible population in Australia, France, Germany, Italy, Spain and the United Kingdom
    Boudewijns, Bronke
    Paget, John
    Del Riccio, Marco
    Coudeville, Laurent
    Crepey, Pascal
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2023, 17 (01)
  • [49] OFF LABEL USE OF INTRAVENOUS IMMUNOGLOGULINS (IVICS): FUNDING MECHANISMS IN FRANCE, GERMANY, ITALY, SPAIN AND THE UNITED KINGDOM (EU5)
    Charafi, N.
    Darnis, Gauthier M.
    Conti, C. C.
    VALUE IN HEALTH, 2015, 18 (07) : A552 - A552
  • [50] Disability-adjusted life years lost due to diabetes in France, Italy, Germany, Spain, and the United Kingdom: a burden of illness study
    Darba, Josep
    Kaskens, Lisette
    Detournay, Bruno
    Kern, Werner
    Nicolucci, Ntonio
    Orozco-Beltran, Domingo
    Ramirez de Arellano, Antonio
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2015, 7 : 163 - 171
12345